Intranasal administration of anti-HMGB1 decreased the Th17 response in the lung. (a) Administration of anti-HMGB1 decreased Th17 cytokine secretion after OVA challenge. BALFs were collected 24 hours after the last OVA challenge. The production of IL-23, IL-17A, IL-4, and IFN- in the BALF of mice in the control, asthma, control IgG-treated, and anti-HMGB1-treated groups was assessed using ELISA. The values represent the means ± standard deviations (). and compared with the asthma group. (b) Administration of anti-HMGB1 downregulated the number of Th17 cells in the lung. Representative results of the percentage of Th17 cells in CD3+ gated lung cells from mice in the control (A), asthma (B), control IgG-treated (C), and anti-HMGB1-treated groups (D) were analyzed using FACS. (c) Histogram showing the number of Th17 cells in mice from the different groups. The values represent the means ± standard deviations (). and compared with the asthma group.
